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Abstract
Xenotropic murine leukemia virus-related virus (XMRV) is a gammaretrovirus that was originally identified from human
prostate cancer patients and subsequently linked to chronic fatigue syndrome. Recent studies showed that XMRV is a
recombinant mouse retrovirus; hence, its association with human diseases has become questionable. Here, we
demonstrated that XMRV envelope (Env)-mediated pseudoviral infection is not blocked by lysosomotropic agents and
cellular protease inhibitors, suggesting that XMRV entry is not pH-dependent. The full length XMRV Env was unable to
induce syncytia formation and cell-cell fusion, even in cells overexpressing the viral receptor, XPR1. However, truncation of
the C-terminal 21 or 33 amino acid residues in the cytoplasmic tail (CT) of XMRV Env induced substantial membrane fusion,
not only in the permissive 293 cells but also in the nonpermissive CHO cells that lack a functional XPR1 receptor. The
increased fusion activities of these truncations correlated with their enhanced SU shedding into culture media, suggesting
conformational changes in the ectodomain of XMRV Env. Noticeably, further truncation of the CT of XMRV Env proximal to
the membrane-spanning domain severely impaired the Env fusogenicity, as well as dramatically decreased the Env
incorporations into MoMLV oncoretroviral and HIV-1 lentiviral vectors resulting in greatly reduced viral transductions.
Collectively, our studies reveal that XMRV entry does not require a low pH or low pH-dependent host proteases, and that
the cytoplasmic tail of XMRV Env critically modulates membrane fusion and cell entry. Our data also imply that additional
cellular factors besides XPR1 are likely to be involved in XMRV entry.
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Introduction
Enveloped viruses must fuse with host cell membranes in order
to gain entry and initiate infection. For retroviruses, this process is
mediated by the envelope glycoprotein (Env) acquired from the
viral producer cells. The Env is initially synthesized as a precursor
in the endoplasmic reticulum (ER) and subsequently cleaved by
cellular proteases in the trans-Golgi complex into the surface (SU)
and transmembrane (TM) subunits [1]. The SU subunit contains a
receptor binding domain (RBD) that is responsible for interactions
with specific cellular receptors or coreceptors, and the TM subunit
possesses a fusion peptide, two heptad repeats (HRs), a membrane-
spanning domain (MSD), and a cytoplasmic tail (CT), all of which
have been shown to control or regulate membrane fusion [2].
Upon proper triggering, the TM subunit undergoes a large scale
conformational rearrangement, leading to the formation of a
stable helix bundle (6-HB) that drives fusion between the viral and
cellular membranes [3].
The retroviral Env-mediated fusion is controlled at multiple
steps to prevent premature activation [2,4]. First, the cleavage of
retroviral Env precursor into SU and TM is a pre-requisite for
fusion as it liberates the fusion peptide located at the amino
terminus of TM so that it can insert into the target membrane
upon triggering [3]. Second, post-translational modifications, such
as glycosylation, are also critical for proper folding and receptor
binding of Env thereby influencing membrane fusion and cell
entry [5,6,7]. In addition, several retroviruses, such as murine
leukemia virus (MLV), Mason-Pfizer monkey virus (M-PMV),
equine infectious anemia virus (EIAV), etc, contain a ,16 amino-
acid stretch in the CT of Env, known as R peptide, that
intrinsically restricts membrane fusion [8,9,10]. In the latter case,
the Env proteins containing the full length CT are not fusogenic in
the virus-producer cells, but become fully fusogenic after viral
protease cleavage of the R peptide upon budding from host cells
[9,11,12]. The mechanism underlying the R peptide-mediated
control of retroviral Env fusion is still not known. Whereas fusion
of most retroviruses is triggered by receptor binding, increasing
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33734numbers of retroviruses have been shown to require a low pH, or
receptor binding plus low pH, for membrane fusion
[13,14,15,16,17,18,19,20]. It is interesting that infection by
ecotropic murine leukemia virus (E-MLV) has been shown to be
blocked by inhibitors of cellular cathepsins [21], suggesting host
proteases are involved in the fusion activation of E-MLV and
perhaps of other retroviruses. Similar mechanisms have been
reported for other enveloped viruses [22,23,24,25,26].
Xenotropic murine leukemia virus-related virus (XMRV) is a
gammaretrovirus that was originallyidentified from human prostate
cancerpatientsandsubsequentlylinkedtochronicfatiguesyndrome
(CFS) [27,28]. However, recent studies have shown that this virus is
a recombinant mouseretrovirus that waslikely generatedduringthe
passages of a human prostate tumor in nude mice [29,30].
Moreover, numerous groups have failed to detect XMRV from
human prostate cancer samples as well as CFS patients, making the
claim of its association with these human diseases questionable
[31,32]. Regardless, it is still important to understand how the Env
protein of XMRV mediates membrane fusion and cell entry from
the virology perspective, especially in light of the emerging diverse
mechanisms of retroviral Env-mediated fusion activation and cell
entry [2]. The Env of XMRV shares significant sequence homology
with that of other xenotropic and polytropic MLVs (X/P-MLV),
especially in the SU subunit, and these viruses share the same
xenotropic and polytropic retrovirus receptor 1 (XPR1) for entry
[27,33,34,35,36]. XMRV has been shown to infect a wide range of
cell lines derived from different species including humans, with the
notable exception of hamster and mouse cells; overexpression of
XPR1 in NIH 3T3 and CHO cells renders these cells susceptible to
XMRV infection, indicating that XPR1 is the key cellular receptor
for XMRV [37,38,39,40,41]. In this study, we aimed to understand
the mechanisms of membrane fusion and cell entry mediated by the
XMRV Env protein, particularly the possible role of its relatively
long CT (compared to Mo-MLV) and of the viral receptor, XPR1,
in modulating this process.
Results
XMRV entry is pH-independent and does not require
cellular proteases
Retroviruses have been historically believed to fuse directly at
the plasma membrane of target cells for entry and infection [42].
However, recent studies have shown that some retroviruses,
including avian sarcoma leukosis virus (ASLV), mouse mammary
tumor virus (MMTV), Jaagsiekte sheep retrovirus (JSRV), enzootic
nasal tumor virus (ENTV), foamy virus, EIAV, and ecotropic
Moloney MLV (MoMLV) require a low pH or low pH-dependent
proteases for cell entry [13,14,15,16,17,18,19,20,21]. Here, we
Figure 1. XMRV entry is pH-independent and does not require host proteases. HTX cells were pre-treated with indicated concentrations of
(A) ammonium chloride, (B) Bafilomycin A1 (BafA1), (C) leupeptin or (D) cathepsin III inhibitor for 1 h and infected with MoMLV pseudotypes
encoding GFP and bearing XMRV Env, MLV 10A1 Env, VSV-G or Ebola GP in the presence of drugs for 6 h before inactivation of remaining virions
using citrate buffer. Percentage of GFP-expressing cells was measured by flow cytometry 48 h post-infection and normalized to the infection
obtained in the absence of drug set to 100%. Shown are at least the averages of 3 independent experiments 6 S.D. ** indicates p,0.01.
doi:10.1371/journal.pone.0033734.g001
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investigated the cell entry of XMRV by using classical chemical
inhibitors that block pH-dependent viral entry [4]. We first treated
human HTX cells (a subclone of HT1080) with a lysosomotropic
agent, NH4Cl, and observed that it did not inhibit but rather
somewhat enhanced XMRV infection (p.0.05). As expected, the
infection of pH-dependent vesicular stomatitis virus (VSV)
pseudovirions was dramatically decreased (p,0.01, Fig. 1A). We
next treated cells with a proton-pump inhibitor, Bafilomycin A1
(BafA1), and found interestingly that XMRV infection was again
increased (p.0.05), yet that VSV entry was almost completely
blocked by BafA1 even at the 5 nM concentration (p,0.01,
Fig. 1B). We noted that entry of 10A1 MLV was also slightly
enhanced by BafA1 (p.0.05), but the effect was not dose-
dependent (Fig. 1B). Similar effects of NH4Cl and BafA1 on
XMRV entry were also observed in 293 and a human prostate
cancer cell line, DU145 (data not shown), together supporting the
idea that XMRV entry does not require a low pH as do the typical
pH-dependent viruses, such as VSV and influenza A [4].
The modest but reproducible enhancement of XMRV infection
in the presence of NH4Cl and BafA1 could be explained by a
block of viral particle degradation in the endosomes or lysosomes.
To investigate this possibility and explore if XMRV entry requires
cellular proteases, we performed pseudoviral infection in the
presence or absence of leupeptin or cathepsin III inhibitor, both of
which are broad spectra, lysosomal protease inhibitors. XMRV
infection was enhanced by both protease inhibitors, albeit the
increase was not statistically significant (p.0.05); however,
infection of Ebola pseudovirions was dramatically impaired
(p,0.01, Fig. 1C and 1D). We noted that VSV infection was
also slightly enhanced by these two protease inhibitors but the
effect was not dose-dependent. The effect of these protease
inhibitors on Ebola infection was consistent with the notion that
Ebola GP-mediated membrane fusion with endosome requires
cellular cathepsin B and L [22,26]. Taken together, these results
show that XMRV entry does not require a low pH or low pH-
dependent cellular proteases, and that endocytosis XMRV may
occur for XMRV but this would likely result in virions inactivation
through pH-dependent host proteases.
Creation of a soluble form of XMRV SU that binds to cells
expressing viral receptor and blocks infection
In order to investigate the role of interactions between XMRV
Env and its receptor XPR1 in modulating membrane fusion and cell
entry of XMRV, we created a soluble form of XMRV SU fused to
the human IgG Fc fragment (Fig. 2A). The fusion protein was
produced by transient transfection of 293T cells and purified using
protein A beads using a procedure we had previously described for
the JSRV SU fusion protein [43]. As shown inFigure 2B, incubation
of XMRV SU-human IgG fusion protein with the permissive HTX
cells resulted in an apparent fluorescence shift relative to that of
secondary antibody alone (which served as a negative control), and
overexpression of XPR1 receptor in HTX cells substantially
increased the XMRV SU binding to the cells, indicating that the
binding was specific. Similar results were also obtained in the
permissive human 293, DU145, A549, dog MDCK, and monkey
Vero cells (data not shown). The specific binding of XMRV SU for
XPR1 was further confirmed in CHO/XPR1 cells which were
established by transduction using a retroviral vector expressing
XPR1; but surprisingly, we reproducibly detected a fluorescent shift
in the parental CHO cells (Fig. 2B), which are known to be
nonpermissive for XMRV infection [37,41] (also see Table 1 below).
We next assessed the effects of purified XMRV SU fusion
protein on pseudoviral infection in HTX cells. Cells were pre-
Figure 2. Soluble XMRV SU binds to cells expressing the viral
entry receptor, XPR1, and blocks XMRV pseudovirion infection.
(A) Schematic representation of XMRV SU-human immunoglobulin (hIgG)
Fc fusion protein. SP:signal peptide. (B) Indicated cell lines were incubated
with 5 mg of XMRV SU-hIgG Fc for 4 h and binding was measured using
anti-human IgG FITC and flow cytometry. Filled: HTX or CHO cells stained
with a FITC-labeled secondary antibody only (HTX/XPR1 or CHO/XPR1 cells
gave a similar background signal which was not overlaid); broken line:
parental HTX or CHO cells stained with XMRV SU plus secondary antibody;
black line: HTX/XPR1 or CHO/XPR1 cells stained with both XMRV SU and
secondary antibody. Representative experiments are shown (n=5). (C, D)
HTXcellswerepre-boundwithindicatedamountsofsolubleXMRVorJSRV
SUfor1 h at 4uCandinfectedwithMoMLVpseudotypes encoding alkaline
phosphatase (AP) and bearing XMRV Env (C) or JSRV Env (D) for 6 h before
inactivation of remaining virions using citrate buffer. AP foci were counted
72 hpost-infectionandvalueswerenormalizedtoinfectionintheabsence
of soluble protein set to 100%. Shown are the averages of 3 independent
experiments 6 S.D. * indicates p,0.05; ** indicates p,0.01.
doi:10.1371/journal.pone.0033734.g002
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1 h at 4uC, followed by switching the temperature to 37uCt o
initiate infection in the constant presence of the fusion protein for
6 h. As shown in Figure 2C, the XMRV SU fusion proteins
substantially blocked the XMRV pseudoviral infection (p,0.05) in
a dose-dependent manner, with the JSRV SU having no apparent
effect (p.0.05). As would be expected, the JSRV SU fusion
protein specifically blocked the JSRV pseudoviral infection but not
that of XMRV (p,0.05) (Fig. 2C and 2D). The concentration of
soluble XMRV SU required to block 50% of XMRV infection
was ,10 ug/ml, which was relatively higher compared that of
JSRV SU (,5 mg/ml, which is necessary to block 50% of JSRV
infection) (Fig. 2C and 2D). Together, these results demonstrate
that the soluble XMRV SU fusion protein interacts with the
XPR1 receptor on the cell surface and functionally blocks the
XMRV pseudoviral infection.
Truncation of XMRV Env from the C-terminal cytoplasmic
tail (CT) promotes SU shedding and syncytia-forming
activity
While identical in the N-terminal and central regions, including
the conserved R peptide cleavage site between 624 and 625, the C-
terminal CT of XMRV Env differs from that of MoMLV Env,
with a relatively longer length (Fig. 3A). Here we sought to
determine the membrane fusion property of XMRV Env,
particularly the effect of CT truncation on cell fusion. We first
created a series of truncation mutants in the CT and examined the
Env processing and expression by metabolic labeling. 293T cells
were pulse-labeled with [
35-S] Met-Cys for 1 h and chased for 4 h;
the XMRV Env proteins in the cell lysates and their SU shed into
the culture media were immunoprecipitated with anti-FLAG
beads (FLAG is tagged at the N-terminus of SU). As shown in
Figure 3B, all the Env constructs were properly processed and
expressed in the transfected cells, except CT635 which consistently
showed a decreased level of expression of the processed SU
(,30% of wildtype) (note the SU subunits of CT624, CT613,
CT609, CT608 and CT606 co-migrated with their full length
precursors because of their reduced size of precursor, Fig. 3B,
upper panel). Of note, CT624, CT613 and CT609 exhibited
enhanced SU shedding into culture media as compared to that of
wildtype and other mutants (Fig. 3B, lower panel). We also
examined the SU surface expression of these Env constructs in
293T cells by flow cytometry using an anti-FLAG antibody, and
observed that CT624 exhibited a wildtype level of expression
whereas all the other truncation mutants had reduced SU on the
cell surface (,50%) (Fig. 3C). Altogether, these results demon-
strate that truncation of the CT of XMRV Env affects SU
shedding and surface expression.
We next performed syncytia-forming assay in 293 cells and
assessed the membrane fusion properties of XMRV Env and
mutants. 293 cells werechosenbecause they are highly transfectable
and also permissive to XMRV infection [41]. The full length
XMRV Env was unable to induce syncytia formation, presumably
due to the presence of an R peptide in the CT (Fig. 4A). CT624 and
CT613, in which the CT of XMRV Env was truncated at the
putative R peptide cleavage site and further towards the N-terminus
(Fig. 3A), respectively, elicited apparent syncytia (typically ,30
syncytia per mg DNA, with .6 nuclei per syncytium) (Fig. 4A).
Interestingly,CT609, whichcontains the firstarginineresidueofthe
CT only, showed a much reduced fusion activity as compared to
CT624 and CT613 (,5–10 syncytia per mg DNA,with smaller size)
(Fig. 4A). These results were somewhat different from what had
been reported for MoMLV, where an identical mutant largely
retained the fusogenicity of R peptide-minus mutant [11,44].
Noticeably, the increased fusion activity of CT624 and CT613, and
to lesser extent of CT609, correlated with the enhanced SU
shedding of these mutants in culture media (Fig. 3B). These results
are similar to our previous findings made on JSRV Env, severe
truncation of which led to pronounced SU shedding accompanied
with greatly increased fusogenicity [19]. Interestingly, we observed
that the tailless CT608 and CT606 mutants were virtually fusion-
defective, possibly due to their truncation into the MSD and/or
reduced surface expression (Fig. 3A and 3C). We further treated the
individual Env-expressing cells with a low pH buffer (pH 5.0) for
1 min or 5 min (pictures not shown), but did not observe apparent
effect on syncytia induction of any of these constructs, supporting
the above conclusion that XMRV Env-mediated fusion and cellular
entry is pH-independent.
Severe truncation of XMRV Env proximal to the
membrane-spanning domain impairs fusogenicity
The finding that syncytia induction can be observed in cells
expressing XMRV Env truncation mutants prompted us to further
quantitatively measure their membrane fusion activities using a
flow cytometry-based cell-cell fusion assay adapted from our
previous studies on JSRV [18,19,45]. In this assay, the effector
293T/GFP cells were transfected with Env-encoding plasmids,
and the target 293 cells were labeled with a red-fluorescent dye,
CMTMR. Consistent with the syncytia formation data, the
XMRV Env wildtype and CT635 were unable to induce cell-
cell fusion as evidenced by no fluorescent dye transfer (,1.8%,
similar to the No-Env background), whereas truncation at the
putative R-peptide cleavage site or further upstream towards the
MSD, i.e., CT624 or CT613, induced apparent cell-cell fusion
(4,5%) (p,0.05) (Fig. 4B and 4C). Again, CT609 showed a
relatively low cell-cell fusion activity (,3%), and the tailless
CT608 and CT606 mutants were incapable of inducing fusion
with background signals (Fig. 4B and 4C). We also examined the
fusion activities of all constructs in 293 cells overexpressing the
XPR1 receptor (293/XPR1), but observed only modest increases
for CT624, CT613 and CT609 (,10–20%). The titers of XMRV
wildtype and mutants in 293/XPR1 cells were approximately 5-
fold higher than those in the parental 293 cells, and the
overexpression of XPR1 in 293/XPR1 cells was confirmed by
flow cytometry using the soluble XMRV SU (data not shown).
Table 1. Titers of XMRV Env pseudovirions in CHO and CHO/
XPR1 cells.
Construct Titer (AP
+ FFU/ml)
CHO CHO/XPR1
XMRV Env ,22 610
4
CT635 ,24 610
3
CT624 ,22 610
3
CT613 ,21 610
2
CT609 ,25 0
CT608 ,23 4
CT606 ,2 ,2
293/GP-LAPSN cells expressing MoMLV Gag-Pol and alkaline phosphatase (AP)
were transfected with plasmids encoding individual XMRV Envs. Virions were
harvested 48–72 h post-transfection, and used to infect CHO and CHO/XPR1
cells expressing XPR1. Titers were determined by counting AP
+ foci 72 h post-
infection. Results of a representative experiment are shown. Experiments were
repeated three times, with similar titers obtained.
doi:10.1371/journal.pone.0033734.t001
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could be due to their different levels of Env expression on the cell
surface or/and intrinsic fusogenicity. To distinguish these possibil-
ities, we transfected effector 293T cells with different amounts of
plasmid DNA encoding individual truncated Envs, and determined
their cell-cell fusion activities and SU surface expression in parallel.
As shown in Figure 5A, the fusion profiles of CT624 and CT613
were almost identical, as evidenced by their similar slopes (,0.095
and ,0.010, respectively, R
2=0.97–0.99). In contrast, CT609
exhibited a slightly decreased slope (,0.068, R
2=0.93), implying
thatitsreducedfusogenicityrelativetoCT624andCT613cannotbe
fully attributable to its low level of surface expression. We further
performed cell-cell fusion using different co-culture periods, i.e., 0, 2,
4, and 8 h, and again observed faster fusion kinetics for CT624 and
CT613 (Fig. 5B) as compared to CT609, further confirming that
additional truncation of XMRV Env beyond the R peptide cleavage
site does not increase fusion activity as we had seen for JSRV Env
and that CT609 has an intrinsically relatively low fusogenicity.
Figure 3. C-terminal truncation of XMRV Env induces SU shedding. (A) Sequence alignment of MoMLV and XMRV Env constructs. MSD:
membrane spanning domain. CT: cytoplasmic tail. Arrow: indicates the MoMLV Env R-peptide cleavage site. Underlined: The CT region that differs
between XMRV and MoMLV. (B) 293T cells expressing XMRV Env were metabolically labeled for 1 h and chased for 4 h. Env proteins in cells lysates
and shed in the culture media were immunoprecipated, resolved by SDS-PAGE and subjected to autoradiography. Band density was measured using
the Quantity One software and values were normalized to the intensity of the XMRV Env SU set to 1.0. Representative experiment is shown (n=2). (C)
The expression of XMRV Env on the 293T cell surface was measured using anti-FLAG and flow cytometry. Fluorescence geometric means were
normalized to XMRV Env (100%). Shown are the averages of 3 independent experiments 6 S.D. XMRV Env: XMRV Env tagged with a FLAG sequence
only at the N-terminus. All truncations were also tagged similarly with an N-terminal FLAG. F-XMRV-F: an XMRV Env construct that is tagged by FLAG
sequences on both N- and C-termini. Mock: untransfected 293T cells.
doi:10.1371/journal.pone.0033734.g003
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CT609, CT608 and CT606 might be due to a block at hemifusion,
we treated co-cultured target and effector cells with chlorpromazine
(CPZ, 0.2–0.5 mM), a membrane permeable reagent that promotes
the transition from hemifusion to full fusion [46], but observed no
apparent increase in fusion for any of these Env constructs (data not
shown). These results suggest that the fusion suppression in these
XMRV Env constructs unlikely takes place at the hemifusion step.
Overall we conclude that, distinct from JSRV Env, severe
truncation of the CT of XMRV Env towards the MSD does not
furtherenhance butratherimpairstheEnvfusogenicity.Thereason
for the decreased fusogenicity of CT609, CT608 and CT606
remains unclear, but is likely related to reduced surface expression
or/and altered Env conformation (see Discussion).
Truncation of XMRV Env causes membrane fusion in
nonpermissive CHO cells but does not confer pseudoviral
infection in the same cell type
We next determined the role of XPR1 in XMRV Env-induced
membrane fusion by using nonpermissive CHO cells and CHO
cells expressing human XPR1 (CHO/XPR1). The CHO/XPR1
cell line was established by transducing CHO cells with a LXSN
Figure 4. C-terminal truncation of XMRV Env in the CT activates its fusion activity. (A) Syncytium-induction assay. 293 cells were
transiently transfected with plasmids encoding the indicated XMRV Env and photographed 24 h post-transfection. Arrows indicate syncytia. (B) Cell-
cell fusion. Effector 293T-GFP cells expressing indicated XMRV Env or no envelope (No Env) were co-cultured for 6 h with CMTMR-labeled target 293
cells and analyzed by flow cytometry. Values shown represent the percentages of fused cells. (C) The fusion percentages (GFP
+/CMTMR
+)o f3
independent experiments performed in duplicate were averaged (6S.D.) and plotted. (D) Binding of XMRV SU to target 293 cells. XMRV SU (2 mg) was
bound to cells for 4 h at 4uC, stained with anti-human IgG FITC, and analyzed by flow cytometry. Red: unstained cells. Blue: secondary alone. Green:
XMRV SU and secondary. A representative experiment is shown (n=4).
doi:10.1371/journal.pone.0033734.g004
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CHO/XPR1 cell line was demonstrated by the specific binding of
soluble XMRV SU fusion protein to those cells as shown in
Figure 2B, and was further confirmed by immunostaining using an
anti-XPR1 antibody (Fig. 6A). The titers of XMRV wildtype and
CT truncation mutants in these two cell lines are shown in Table 1.
CHO cells were apparently not susceptible to XMRV Env
pseudoviral infection (Table 1), consistent with previous reports
from other groups [38,39,40,47]. Overexpression of XPR1 in
CHO cells resulted in a titer of 10
4 IU/ml for the wildtype and
somewhat reduced titers for the CT truncation mutants (Table 1).
Overall, these data support the notion that XPR1 is a critical
cellular receptor for XMRV.
The cell-cell fusion activities of XMRV Env and mutants in
CHO and CHO/XPR1-expressing cells were then examined. For
this purpose, we labeled CHO or CHO/XPR1 cells with
CMTMR, and co-cultured them with the effector 293T/GFP
cells expressing XMRV Env or truncation mutants plus GFP. We
observed that, surprisingly, CT624 and CT613 reproducibly
induced a detectable level of cell-cell fusion activity in the non-
permissive CHO cells (p,0.05) (Fig. 6B), despite the fact that this
cell line is nonpermissive for XMRV infection (Table 1).
Interestingly, overexpression of human XPR1 in CHO cells only
slightly increased the fusion activities of XMRV Env CT mutants,
CT624 and CT613 (Fig. 6B), despite their significantly increased
pseudoviral titers (Table 1). These results, along with the data
using 293/XPR1 cells described above, imply that XPR1 may not
be the sole trigger for XMRV Env-mediated membrane fusion
and cell entry.
Incorporations of XMRV Env into retroviral and lentiviral
vectors are impaired by CT truncations resulting in
reduced transduction efficiency
The CT of retrovirus Env plays various roles in the replication
cycle, including entry and assembly; this has been mostly studied
in HIV-1 [48]. Here, we wished to determine the ability of XMRV
Env and CT truncation mutants to pseudotype the MoMLV
retroviral and HIV-1 lentiviral vectors as well as its relationship to
membrane fusion and cell entry. As shown in Table 2, all the
XMRV Env constructs (tagged with a FLAG sequence at the N-
Figure 5. Truncation beyond the putative R-peptide cleavage
site does not further enhance the XMRV Env fusion activity. (A)
Effect of Env expression on cell-cell fusion. Effector 293T/GFP cells were
transfected with different amounts of plasmids encoding indicated
XMRV Env, and co-cultured with target CMTMR-labeled 293 cells. Fusion
percentages were determined by flow cytometry following 6 h
incubation. In parallel, the XMRV Env surface expression was measured
by flow cytometry using an anti-FLAG antibody. The obtained fusion
percentages were plotted against Env surface expression. A represen-
tative experiment with standard errors of triplicate samples is shown
(n=3). (B) Effect of incubation time on cell-cell fusion. Effector 293T/GFP
cells expressing indicated XMRV Env were co-cultured with target
CMTMR-labeled 293 cells and cell-cell fusion was assessed after different
periods of incubation time. A representative experiment with standard
errors of triplicate sample is shown (n=3).
doi:10.1371/journal.pone.0033734.g005
Figure 6. Cell-cell fusion activities of XMRV Env and mutants in
CHO or CHO cells expressing XPR1. (A) Immunostaining of CHO
and CHO/XPR1 cells. Cells were fixed, permeabilized, stained for XPR1
using anti-XPR1 and FITC-coupled secondary antibodies, and counter-
stained using DAPI. (B) XMRV Env truncation mutants can induce cell-
cell fusion in non-permissive CHO cells. Effector 293T/GFP cells
expressing indicated XMRV Env were co-cultured for 6 h with target
CMTMR-labeled CHO or CHO cells expressing XPR1 (CHO/XPR1) and
analyzed for fusion by flow cytometry. Shown are the averages of 3,6
independent experiments 6 S.D. * indicates p,0.05.
doi:10.1371/journal.pone.0033734.g006
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distinct efficiencies. The full length XMRV Env exhibited
approximately 2610
4 infectious units per ml for both vectors
(Table 2, and data not shown), similar to a recent report [49]. The
titers of MoMLV retroviral pseudotypes harbouring CT635 or
CT624 were slightly reduced as compared to that of the wildtype
Env (,4–6 fold), whereas the other more severely truncated
mutants exhibited a 2,3-log decrease in the infectious titer
(Table 2). Similar patterns were also observed for the HIV-1
lentiviral pseudotypes (Table 2), but interestingly we found that
CT635 consistently exhibited pronounced reductions in the
lentiviral pseudoviral titers (,100 fold) as compared that of
MoMLV retroviral pseudotypes (,6-fold). The generally reduced
viral titers for the CT truncations cannot be fully explained by the
enhanced SU shedding, at least for some of these mutants, but
appeared to correlate with the differential levels of SU surface
expression (Fig. 2C). We also examined the incorporation
efficiencies of these Envs into the MLV pseudovirions by Western
blot using concentrated pseudoviral particles, and detected similar
levels of SU for CT624, CT613, CT609 and the wildtype Env, as
compared to CT635, CT608 and CT606 for which the SU
incorporation efficiency was greatly reduced (Fig. 7). We have
attempted to detect the XMRV TM in viral producer cells and the
viral particles using an antibody against the MoMLV TM but
without success (a gift from Marc Johnson, data not shown).
Nevertheless, the Env incorporation data based on the SU (Fig. 7)
and the XMRV pseudotype titers shown in Table 2 correlated
with the SU expression profiles shown in Figure 3C. We noticed
that the titers of pseudoviral infection for CT624 and CT613 did
not correlate with their enhanced Env fusogenicity based on the
syncytia formation and cell-cell fusion assays, and this was
particularly the case for CT613, which showed a strongly
enhanced fusogenicity (Figs. 4 and 5) but a much reduced titer
relative to the wildtype Env (Tables 1 and 2).
Discussion
Retroviruses use distinct mechanisms for membrane fusion and
cell entry, the mechanisms of which are still poorly defined. In this
report, we provided evidence that XMRV entry does not require a
low pH or pH-dependent host proteases, but uses a mechanism
that is similar to that of typical pH-independent viruses.
Interestingly, we find that XMRV entry is enhanced by NH4Cl
and BafA1, the two most commonly used agents that neutralize
acidic endosomal environments, as well as by leupeptin and
cathepsin inhibitor III, which broadly inhibit the lysosomal
protease activities. Together, these observations suggest that
endocytosis may occur in non-productive entry of XMRV, leading
to viral particle degradation. Consistent with this notion, we did
not observe specific block of XMRV entry by Dynasore or a
dominant negative mutant of Dynamin (K44A) in 293T cells (data
not shown). Previous studies have shown that different endocytic
pathways mediate entry of some pH-independent retroviruses,
including amphotropic and ecotropic MLV as well as HIV-1
[21,50,51], however the exact mechanisms and the underlying
significance remain largely unknown. It should be added that,
while we have not observed any inhibitory effects of leupeptin and
cathepsin III inhibitor on XMRV infection in HTX and 293 cells,
we cannot rule out the possibility that cellular proteases may be
involved in the XMRV entry of other cell types. In this sense, it is
interesting to note that endocytosis and cathepsins were recently
shown to affect the entry of several gammaretroviruses, including
XMRV, in human TE671 and rat XC cells [52]. Additional
studies are warranted to clarify this issue and further characterize
the entry pathway of XMRV, perhaps with assistance of the
recently developed single molecule labeling and confocal imaging
technique.
One important objective of this study was to understand the
possible roles of the CT of XMRV Env in modulating membrane
fusion and cell entry. We showed here that CT624 and CT613,
which are truncated at or beyond the putative R peptide cleavage
site of the XMRV Env (Fig. 3A), induced apparent syncytia
formation and cell-cell fusion in permissive 293 cells (Figs. 4 and
5), presumably due to the removal of the putative R peptide.
Surprisingly, we observed apparent cell-cell fusion of CT624 and
CT613 also in CHO cells (Fig. 6B), which are known to be non-
permissive for XMRV infection, including these two truncation
mutants (Table 1). These results suggest two possibilities: first,
CHO cells may express a low but functional level of XPR1 that
permits cell-cell fusion of XMRV Env mutants and that the
resistance of CHO cells to XMRV infection may be due to a block
at the post-fusion steps. This possibility is supported in part by our
observation that a soluble form of XMRV SU fusion protein
reproducibly binds CHO cells relative to the negative control
using secondary antibody alone (Fig. 2). These binding results also
argue against the possibility that potential N-linked glycosylation
of XPR1 in CHO accounts for its resistance to XMRV infection, a
situation that has been previously shown to be the case for several
retroviruses [53,54]. Second, the XPR1-mediated binding may
Figure 7. XMRV Env incorporations into an MLV retroviral
vector. 293/GP_LAPSN cells were transfected with an XMRV Env-
encoding plasmid, and viral particles were purified through ultracen-
trifugation. Concentrated viruses were subjected to Western blot using
an anti-FLAG antibody to detect XMRV SU (upper panel) or an anti-MLV
gag antibody to examine MLV Gag (lower panel).
doi:10.1371/journal.pone.0033734.g007
Table 2. Titers of MLV and HIV-1 vectors bearing XMRV Env
and truncation mutants.
Construct
MLV vector
(AP+ FFU/ml)
HIV vector
(IU/ml)
XMRV Env 5.1610
4 1.6610
4
CT635 8.4610
3 1.8610
2
CT624 1.4610
4 6.2610
3
CT613 7.9610
2 4.4610
2
CT609 4.0610
2 2.8610
2
CT608 8.8610
2 2.3610
2
CT606 4.1610
2 50
The MLV titers were determined as described in Table 1 except HTX cells were
used for infection. For HIV-1 lentiviral vectors, 293T cells were transfected with a
plasmid encoding HIV-1 Gag-Pol, an HIV-1 vector expressing GFP and a plasmid
expressing XMRV Env or truncation mutant. Virions were harvested 48–72 h
post-transfection, and used to infect HTX cells. Titers were determined by
detecting GFP
+ cells 48 h post-infection. Results of a typical representative
experiment are shown. Experiments were repeated three times, with similar
titers obtained.
doi:10.1371/journal.pone.0033734.t002
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fusion. This scenario is in line with our finding that overexpression
of XPR1 in 293 and CHO cells did not significantly increase the
cell-cell fusion activities of XMRV Env truncation mutants despite
their increased infection in these cells (Fig. 6B and Table 1; data
not shown). We also considered the possibility that the XMRV
Env truncation mutants may have acquired a receptor-indepen-
dent, spontaneous cell-cell fusion or are pre-activated in 293T/
GFP cells due to their reduced kinetic barrier required for
membrane fusion; however, the lack of infection in the CHO cells
for the truncation mutants did not support this hypothesis
(Table 2). Taken together, we favour the notion that, while
XPR1 is a critical receptor for XMRV and is required for
membrane fusion and cell entry, other cellular factors as yet to be
identified are likely to be involved in cell entry and membrane
fusion of XMRV. Consistent with this idea, it has been recently
reported that XMRV does not infect BHK cells even when XPR1
is overexpressed in this cell line [47], and that XMRV can infect
A549 cells even though this cell line does not express a functional
XPR1 receptor [55]. Hence, identification of additional cellular
factors involved in XMRV entry would help to better understand
the mechanisms of membrane fusion and cell entry mediated by
XMRV Env.
Previous studies from HIV and other simple retroviruses have
suggested that the enhanced fusion activities of some retroviral
Env truncations in the CT may be due to increased steady-state
levels of Env expression on the cell surface [56,57,58,59].
However, here we have found little evidence that suggests that
this might be the case for XMRV (Fig. 3C) - despite the highly
conserved endocytosis motif, YXXh (Y=tyrosine, X=any amino
acid, h=residue with hydrophobic side chain) present in the CT of
XMRV Env (Fig. 3A). Another commonly assumed mechanism is
that truncation of the retroviral Env CT can somehow alter the
conformation of Env ectodomain, resulting in a reduced
association between SU and TM thereby promoting membrane
fusion [60]. Indeed, we observed that all three truncation mutants
with enhanced fusogenicities, i.e., CT624, CT613 and CT609,
exhibited increased levels of SU shedding, which was in sharp
contrast to that of wildtype Env and other mutants (CT635,
CT608 and CT606) having minimal cell-cell fusion activity
(Fig. 3B, Figs. 4 and 5). Future studies will focus on how the CT
of XMRV Env structurally modulates the Env fusion activation.
Another surprising finding of this study is that CT609, which
harbours the single arginine residue in the CT possesses a reduced
fusogenicity relative to that of CT624 and CT613, which cannot
be solely explained by its reduced surface expression (Figs. 4, 5,
and 6). This observation is clearly different from what we had seen
for JSRV Env [19] and is also somewhat different from some
though not all of the previous studies on MoMLV [11,44,61].
Importantly, the tailless mutants, CT608 and CT606, are virtually
fusion-defective (Fig. 4), collectively leading us to propose that the
N-terminal CT proximal to the MSD of XMRV Env is critical for
Env-mediated membrane fusion. One possible mechanism is that
residues in this region, including the highly conserved arginine
present in many transmembrane proteins including the retroviral
Envs, may interact with cell membrane and thus modulate lipid
movement during the membrane fusion process [62,63].
Despite enhanced fusogenicity of CT624 and CT613, we found
that the infection efficiency of their pseudovirions were rather low
compared to those of wildtype Env (Tables 1 and 2). One plausible
explanation is that the incorporations of these truncations into the
MoMLV and HIV-1 vectors might be reduced as compared to
those of wildtype; however, based on our immunoblot analysis
using an anti-FLAG antibody to detect the XMRV SU, we found
no evidence to support this scenario (Fig. 7). Alternatively, the
reduced pseudoviral titers for the truncation mutants might result
from their altered ability to bind to the viral receptor, XPR1.
While we do not have direct evidence in support of this possibility,
the apparent SU shedding induced by the CT truncations in the
Env-expressing cells (Fig. 3B) strongly suggests that conformational
changes likely occurs in the ectodomain of the truncated Env,
including their SU subunits. Indeed, prior studies from HIV and
other retroviruses have demonstrated that CT truncation of
retroviral Env can alter the Env receptor binding capability thus
affect viral infection [60,64]. In this regard, it would be interesting
to explore the role of the CT of XMRV Env in the infectious virus
system.
Materials and Methods
Cell lines, antibodies and reagents
The HTX (a subclone of HT1080), 293T, 293, 293T/GFP
(293T cell line stably expressing GFP) and 293/GP-LAPSN (293
cells stably expressing MoMLV Gag-Pol and alkaline phosphatase
or AP) cell lines have been previously described [19,65]. The 293/
XPR1, HTX/XPR1 and CHO/XPR1 cell lines were generated
by transducing the 293, HTX or CHO cells using a retroviral
vector, LXSN, encoding the XPR1 receptor (LhXPR1SN, kind
gift of Dusty Miller) [33] and bearing VSV-G. Infected cells were
selected using G418 (Invitrogen, Carlsbad, CA) for ,10 days. All
cell lines were cultured in DMEM (Invitrogen) supplemented with
10% fetal bovine serum (FBS) at 37uC at 10% CO2-air
atmosphere at 100% relative humidity.
The anti-FLAG monoclonal antibody, the EZview Red anti-
FLAG affinity gel, and anti-mouse immunoglobulin G (IgG)
coupled to phycoerythrin (PE) were purchased from Sigma (St.
Louis, MO). The secondary anti-human IgG antibody coupled to
fluorescein isothiocyanate (FITC) was purchased from DAKO
Cytometer (Glostrup, Denmark). The anti-XPR1 antibody was
purchased from Abcam (Abcam, Cambridge, MA). The red
fluorescent dye 5-(and-6)-([{4-chloromethyl}benzoyl}amino)tetra-
methylrhodamine (CMTMR) and Lipofectamine 2000 were
purchased from Invitrogen (Carlsbad, CA). Ammonium chloride,
chlorpromazine (CPZ), 49,6-diamidino-2-phenylindole (DAPI)
were purchased from Sigma (St. Louis, MO). Bafilomycin A1
(BafA1), leupeptin hemisulfate and cathepsin inhibitor III were
purchased from Calbiochem (Darmstadt, Germany). The [
35S]
Methionine and [
35S] Cysteine cell labeling pro-mix was
purchased from Amersham (Buckinghamshire, England).
XMRV Env constructs
XMRV Env was initially engineered to contain a FLAG tag at
both N- and C-termini by using pcDNA3.1-VP62 (gift of Robert
Silverman) [37] as a template for PCR, and cloned in a pCIneo
expression vector (Promega, Madison, WI), the resulting construct
was referred to as pCIneo-F-Xenv-F. To create the N-terminal
FLAG-tagged XMRV Env wildtype and CT truncations, the
pCIneo-F-Xenv-F construct was used as a template, with the
following lower primers being used for PCR amplification (Not I
sites are underlined): XMRV Env, 59- ATCGGCGGCCGCT-
CATTCACGTGATTCCACTTC-39; CT635, 59- TTCTGCG-
GCCGCTCATGATTTGAGTTGGTGATA-39; CT624, 59-C-
TGTGCGGCCGCTCACAGGGCCTGCACTACCGA-39; CT-
613, 59-AATTGCGGCCGCTCAAAACTGGACCAAGCGGT-
TG-39; CT609, 59-TACAGCGGCCGCTCAGCGGTTGAGA-
ATACAGGGTCCGA-39; CT608, 59- AAACGCGGCCGCT-
CAGTTGAGAATACAGGGTCCGA-39; CT606, 59- GACC-
GCGGCCGCTCAAATACAGGGTCCGAAGA-39. The pCI-
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been previously described [18].
The soluble XMRV SU construct was generated by overlapping
PCR using pcDNA3.1-VP62 [37] and the previously described
pCSI-JSU (for JSRV SU fusion protein) [43] as templates. The
first fragment containing XMRV SU was amplified using the
following primers: upstream primer (Not I underlined), 59-
GCATGCGGCCGCATGGAAAGTCCAGCGTTCTC-39; do-
wnstream primer, 59-CCTAGGCCTGTCGACGCCTTTTCA-
AACTGGCC-39. The second fragment containing human IgG Fc
was generated using the following primers: upstream primer, 59-
GGCCAGTTTGAAAAGCTGTCGACAGGCCTAGG -39; do-
wnstream primer, 59- TGTATCTTATCATGTCTGGATC-
CCC-39. The XMRV SU fused to the human IgG Fc was
generated using the two fragments as templates, and the upstream
and downstream primer of the first and second fragment,
respectively, and then the PCR product was cloned into the pCSI
vector.
Viruses and infection
The MoMLV retroviral pseudotypes encoding the alkaline
phosphatase (AP) were produced by transfection of 293/GP-
LAPSN cells with plasmid DNA encoding individual XMRV Env,
CT truncations, or JSRV Env. The MoMLV retroviral pseudo-
types encoding the green fluorescent protein (GFP) were generated
by co-transfection of 293T cells with pCMV-gag-pol-MLV,
pCMV-GFP-MLV (both vectors are kind gifts of Franc ¸ois-Loı ¨c
Cosset) and plasmids encoding XMRV Env, XMRV Env CT
truncations, Ebola GP (pCIneo-Ebola GP) [18], VSV-G (pMD.G),
or MLV 10A1 Env (pCIneo-10A1) [18]. The HIV-1 lentiviral
pseudotypes encoding AP were produced by co-transfecting 293T
cells with pCMV-HIVD8.2, pHR’CMVAP [66] and plasmid
DNA encoding individual Envs. All pseudotypes were harvested
48 and 72 h post-transfection and cell debris were removed by
centrifugation at 2,5006g. MLV pseudovirions were purified by
ultracentrifugation on a 20% sucrose cushion for 2 h at 185,0006
g and 4uC, and Western blot was performed to examine SU
incorporation using an anti-FLAG antibody. All viral infections
were carried out in the presence of 5 mg/ml polybrene (Sigma) and
viral titers were determined by AP staining or flow cytometry
analysis to measure GFP
+ cells 48–72 h post-infection. For
infection in the presence of drugs or soluble XMRV SU or JSRV
SU, cells were first pre-treated with the indicated concentrations of
drugs at 37uC or the soluble proteins at 4uC for 1 h, and then
incubated with retroviral pseudotypes for 6 h in the presence of
drugs or fusion proteins before inactivation using citrate buffer
(40 mM sodium citrate, 10 mM KCl, 135 mM NaCl, pH 3.15).
Syncytium induction and cell-cell fusion assays
The syncytium induction assay was performed as described
previously with some modifications [6,19]. 293 cells were co-
transfected with plasmids encoding XMRV Env or CT truncation
mutants plus a GFP-encoding plasmid in order to monitor the
transfection efficiency and syncytia formation. Syncytia formation
was typically observed and photographed 24 h post-transfection.
Where applicable, cells were treated for 5 minutes at 37uC with
pre-warmed pH 5.0 buffer (phosphate-buffered saline (PBS),
10 mM MES, 10 m M HEPES) or 0.2–0.5 mM CPZ for 1 min
and incubated in normal growth media at 37uC for 1 h.
The cell-cell fusion assay was performed as described previously
[19,45]. Briefly, effector 293T/GFP cells were transfected with
plasmid DNA encoding XMRV Env or CT truncation mutants
using Lipofectamine 2000 (Invitrogen). Twenty-four hours later,
cells were washed with PBS and detached using PBS containing
5 mM EDTA. Target 293, 293/XPR1, CHO, or CHO/XPR1
cells were detached using PBS-5 mM EDTA and labeled with
3.5 mM CMTMR in serum-freemedia for 30 min at 37uC, washed,
incubated for an additional 30 min at 37uC in fresh media and
washed 3 times with media. Effector cells and target cells were co-
cultured on 24-well plates for the indicated time periods. Cell-cell
fusion was measured by flow cytometry using FACSCalibur (BD
Bioscience, Missauga, Canada). The surface expression of XMRV
Env in the 293T/GFP cells was measured by flow cytometry using
the anti-FLAG antibody and anti-mouse IgG coupled to PE.
Production of XMRV SU fusion protein and its binding to cells
Soluble XMRV SU and JSRV SU fusion proteins were
produced as described previously [43]. 293T cells were transfected
using the calcium-phosphate method with plasmids encoding the
different SU. Twelve hours post-transfection, media were replaced
with DMEM supplemented with 2% ultra-low IgG FBS (Invitro-
gen). The proteins in the media were purified using protein A
beads (GE Healthcare, Uppsala, Sweden) and analyzed by SDS-
PAGE and Sypro Ruby staining (Bio-Rad, Hercules, CA).
XMRV SU binding assays were performed as described
previously [6,43]. Cells were incubated with 2–10 mg of soluble
XMRV SU-IgG fusion protein for 3–4 h on ice, washed 3 times
with PBS-2% FBS and incubated with anti-human IgG coupled to
FITC for detection. Fluorescence was measured by flow cytometry
using FACSCalibur (BD Bioscience, Missauga, Canada).
Immunostaining
CHO or CHO/XPR1 cells were fixed using 4% paraformalde-
hyde in PBS, permeabilized using 0.5% Triton X-100 and stained
using anti-XPR1 and anti-rabbit IgG coupled to FITC. Before
mounting the slides, cells were counterstained with the nuclear stain
DAPI. Pictures were taken using a fluorescence microscope (Carl
Zeiss, Goettingen, Germany) and images were processed using the
ImageJ software (U.S., National Institutes of Health).
Metabolic labeling
Metabolic labeling was performed as previously described
[19,45]. Briefly, 293T cells were transfected using the calcium-
phosphate method with plasmid DNA encoding individual Env.
Twenty-four hours later, cells were starved in cysteine and
methionine-free DMEM for 30 minutes, pulse-labeled with
62.5 mCi
35S-cysteine and –methionine for 1 h at 37uC, washed
with fresh media and chased for 4 h at 37uC in complete growth
medium. Media were then collected and cells washed and lysed
(50 mM Tris pH 8.0, 150 mM NaCl, 0.4 mM EDTA, 1% Triton
X-100, 0.1% NP-40, 10 mg/ml aprotinin (Sigma), 10 mg/ml
leupeptin (Sigma) and 1 mM phenylmethylsulfonyl fluoride
(Sigma). The XMRV Env proteins in media and in cell lysates
were immunoprecipitated using anti-FLAG beads and resolved by
SDS-PAGE. Dried gels were autoradiographed and band
intensities of XMRV SU in the cultured media were quantified
using the Quantity One software (Bio-Rad, Hercules, CA).
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